Table 1.

Patient demographics and disease characteristics

	No Zoledronic Acid (N = 59)	Zoledronic Acid (N = 60)
Median Age (Range)	47 (31–68)	49 (29–67)
Race, N (%):
Caucasian	45 (76.3)	39 (65.0)
African-American	11 (18.6)	20 (33.3)
Hispanic	0	1 (1.7)
Asian	3 (5.1)	0
Menopausal Status, N (%):
Premenopausal	33 (55.9)	31 (51.7)
Postmenopausal	26 (44.1)	29 (48.3)
Pathology, N (%):
Ductal carcinoma	49 (83.1)	47 (78.3)
Lobular carcinoma	7 (11.8)	7 (11.7)
Other	3 (5.1)	6 (10)
Mean tumor size, cm (s.d.)	3.56 (2.41)	3.81 (2.03)
Lymph-node positive, N (%)	33 (55.9)	38 (63.3)
Grade, N (%)
I	2 (3.4)	7 (11.7)
II	28 (47.5)	20 (33.3)
III	29 (49.2)	33 (55)
Receptor status, N (%)
ER+	34 (57.6)	32 (53.3)
PR+	31 (52.5)	24 (40)
HER2+	10 (16.9)	13 (21.7)
ER+/HER2−	29 (49.2)	26 (43.3)
ER−/PR−/HER2−	17 (28.8)	20 (33.3)
Unknown	1 (1.7)	-